We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Low-Volume Aldosterone Immunoassay Validated for Small Samples

By LabMedica International staff writers
Posted on 26 Sep 2017
Heart failure is a severe cardiovascular disease in adults and children and is characterized by structural or functional abnormalities of the heart. More...
Heart failure leads to an inappropriate blood circulation and subsequently to an undersupply of metabolizing tissues with oxygen and nutrients.

The humoral parameter aldosterone is part of the renin-angiotensin-aldosterone system (RAAS), which plays a major role in the body's salt and water balance. In clinical settings, serum aldosterone is recommended as a screening and diagnosis parameter for primary aldosteronism in high-risk patients.

Scientists at the Heinrich-Heine-University Düsseldorf (Germany) developed and validated a bioanalytical assay for the determination of aldosterone concentrations in small sample volumes. An immunoassay was developed based on a commercially available aldosterone enzyme-linked immunosorbent assay (ELISA) kit. Serum samples were donated by healthy volunteers. The optical density was measured using the absorbance reader infinite F50.

The investigators reported that the assay with a range 31.3 pg/mL to 1,000 pg/mL (86.9 pmol/L to 2,775 pmol/L) was characterized by a between-run accuracy from − 3.8% to − 0.8% and a between-run imprecision ranging from 4.9% to 8.9% (coefficient of variation). For within-run accuracy, the relative error was between − 11.1% and + 9.0%, while within-run imprecision ranged from 1.2% to 11.8% (CV). For parallelism and dilutional linearity, the relative error of back-calculated concentrations varied from − 14.1% to + 8.4% and from − 7.4% to + 10.5%, respectively. No impact of hemolysis on accurate sample determinations was observed.

The authors concluded that their present immunoassay is compliant with current bioanalytical guidelines of the European Medicines Agency (EMA) and allows accurate and precise aldosterone determinations in 40 µL serum. As the assay runs with low-volume samples, it is especially valuable for pediatric investigations, but is not limited to this population. The study was published originally published online on July 27, 2017, in the journal Practical Laboratory Medicine.

Related Links:
Heinrich-Heine-University Düsseldorf



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.